DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Lebrikizumab is an investigational drug.
There have been 20 clinical trials for Lebrikizumab. The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Asthma, Dermatitis, Atopic, and Dermatitis. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and Dermira, Inc.
There are eleven US patents protecting this investigational drug and three hundred and twenty-seven international patents.
Recent Clinical Trials for Lebrikizumab
|A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis||Dermira, Inc.||Phase 2|
|A Study to Evaluate Safety and Efficacy of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease (COPD)||Hoffmann-La Roche||Phase 2|
|A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting||Hoffmann-La Roche||Phase 3|
Top disease conditions for Lebrikizumab
Top clinical trial sponsors for Lebrikizumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Lebrikizumab||Start Trial||Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders||Knopp Biosciences LLC (Pittsburgh, PA)||Start Trial|
|Lebrikizumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Lebrikizumab||Start Trial||Compositions and methods for treating chronic urticaria||Knopp Biosciences LLC (Pittsburgh, PA)||Start Trial|
|Lebrikizumab||Start Trial||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|